• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    3-N-formyl derivatives of 3'',6'-di-N-acyl-kanamycin A and 2',3'',6'-tri-N-acyl-kanamycin B, process for their preparation, and their use as intermediates for production of antibacterially active 1-N-(substituted) derivatives of kanamycins A and B by alkylation and subsequent removal of the formyl and acyl groups.
    公开号:SU873889A3
    申请号:SU792807718
    申请日:1979-09-06
    公开日:1981-10-15
    发明作者:Барри Томас Майкл
    申请人:Пфайзер Корпорейшн(Фирма)；
    IPC主号:
    专利说明:

    is obtained by alkylation of intermediates of the general formula. 1, where R and R are as defined, resulting in a compound of the formula
    where rl, r and r3
    matter. above
    the formyl group and the R group are removed by conventional methods and the compound of formula G is isolated.
    The intermediate bN-substituted 3-N-formylcamycin compounds of the formula D above are new compounds, and in accordance with the present invention, they are prepared according to a method based on the known amine formulating reaction,
    According to the process for the preparation of 6-L-substituted 3-N-formylcanamycin of general formula I, the compound of general formula
    BUT ..cJHzNHB
    -NO J | h
    NNG
    where R and R are as defined above,
    is formulated with 4-nitrophenyl formate in an aqueous solvent in the presence of a base, and the resulting compound is subjected to selective hydrolysis to remove the formyl group from the 1-amino position, while the formyl group at the 3-position remains intact. Selective hydrolysis is carried out by diluting with a solution of sodium or potassium hydroxide at a pH of 12.0-12.5.
    - As the starting compound, 1, b-di-N-acetyl {canamycin A or 2, b, b-tri-N-acetylcanamycin B,
    - Suitable solvents for carrying out the reaction are aqueous dioxane, aqueous tetrahydrofuran or dimethylformamide, the reaction is carried out by adding in portions of excess. (for example, triple) 4 -nitrophenyl formate to a derivative of kanamycin.
    To facilitate the reaction, an organic base is added to the mixture, for which, for example, triethylamine can be used. For each reactive amine group, it is preferable to introduce at least one equivalent of base. The formylation reaction usually ends in about 24 hours at room temperature, after which the product can be removed by conventional methods, for example by evaporation of the solvent or by precipitation, and if necessary, the product can be further purified.
    The step of selective hydrolysis is usually carried out using -. 1,3-di-L-formyl compound and dissolved in a water or aqueous organic solvent, for example, aqueous dioxane or aqueous tetrahydrofuran, using a dilute sodium or potassium hydroxide solution and the pH of the solution is carefully adjusted to values within 12, 0-12,5. The solution is stirred at room temperature for several days, and the course of the reaction is monitored by thin layer chromatography until conversion to 3-N-forms of formula 1 is completed. The solution is then neutralized by adding acid or, more conveniently, by adding ion exchange resin in the form. The advantage of this is to prevent the accumulation of inorganic material in the solution, as well as the absorption by the resin of any by-products that can cleave both 1 and 3-formic. The product is finally isolated by conventional methods, for example, by evaporation to a small volume and by precipitation of an organic solvent, for example, isopropanol. If necessary, the product can be further purified by chromatographic purification, but in general it is sufficiently pure for use. Directly in reactions for the preparation of compounds of formula I
    The method of producing compounds of formula 1 can be carried out using 3H, b-di L-acetylcanamycin A to obtain a compound of formula 11 / in which H is acetyl and R is hydroxy group. Similarly, for the preparation of a compound of formula 1 in which R is a group R is acetyl, 2, 3, b and three N-acetylcanamycin B can be used.
    权利要求:
    Claims (3)
    [1]
    Thin layer chromatography was carried out on silica plates using the indicated solvent system. The spots are observed after drying the plates by spraying a 5% solution of tert-butyl hypochlorite in cyclohexane on them, and drying the plates at 10 minutes in a thermostat with ventilation, cooling and spraying with a solution of starch and potassium iodide. Thin-layer electrophoresis was carried out on 20 cm silica plates with a potential difference of 900 V 45 min. The electrolyte is a mixture of formic and acetic acids with pH 2 / determination is made as described above. Example 1. Getting 3, b - di-N-acetyl-Z-N-formylcanamycin A A). To a suspension of β, b-acetyl kanamycin A (3.9 g) in water (21 ml) and tetrahydrofuran (21 ml) containing triethylamine (6.91 g), 4-nitrophenyl formate ( 6.88 g). The reaction mixture is stirred overnight and then evaporated to a small volume, displacing the last traces of water by azeotropic distillation with isopropinol (final volume 35 ml) 3,6-di-M-acetyl-1, 3-di-L-form are precipitated from the solution canamidine A (2.41), which is then filtered and dried by vacuum at 50 ° C. For thin layer electrophoresis (pH-2), the compound will give a value of 0.09, corresponding to kanamycin A. Thin layer chromatography, using methanol, ethyl acetate, ammonia, water (40: 40sl: 30) as eluent, gives the value of R. AT). The product obtained under A (2.4 g) is dissolved in water (72 ml} and the pH of the solution is adjusted to 12.0-12.5 with 2N sodium hydroxide solution (2.0 ml). The solution is stirred at room temperature for 7 days, maintaining the pH between 12.0 and 12.5, and then neutralized with Amberlite 1R120 (mA) (10 ml) ion exchange resin. The resin is filtered and the filtrate is concentrated to a small volume, and traces of water are removed by displacement with dimethylformamide ( 5 mp) by refluxing. Then, propylene sulfol (30 MP) and precipitate H, B-di-N-acetyl-3-N-formylcanamycin A (1.75 g), filtered and dried under vacuum at 40 C. The resulting compound is clean enough so that it can be used at the next stage about ; ca A sample of this compound was subjected to further chromatographic chromatography on CM Sephadex G 25 (W Form), where a 0.1 M ammonium hydroxide solution is used as the eluent. The NMR spectrum of this compound fully meets the required structure and confirms the monoformylation of the 3-amino group. Metoma thin-layer electrophoresis (pH-2) obtained value. 0.43, corresponding to kanamycin A. Thin layer chromatography, where a mixture of methanol, ethyl acetate, attchmac, water (40: 40: 1: 30) is used as eluent (a value of R 0.23 is obtained. Example 2. Preparation 2, h, 6-tri-m-acetyl-3-N-formylcanamycin B. A). To a solution of kanamycin B sulfate (80.5 g) and sodium carbonate (76 g) in water (400 ml), benzyl chloroformate (128 g) is added for 10 minutes and the solution is stirred for 1 hour at room temperature. The solution is collected by filtration, washed with water, diluted hydrochloric acid and water and dried to obtain a penta-L-benzyloxycarbonylcanamycin B. Yield 125.7 g. B). Penta-N-benzyloxycarbonylcanamycin B (230.8 g) is added in 15 min small portions to a stirred solution of acetic anhydrite (189 ml) in pyridine (346 ml) and dichloromethane (346 ml), the suspension is stirred at room temperature for 48 hours The solution is poured into a mixture of dichloromethane (1.5 l) and water (2.3 l). The organic phase is separated and washed with dilute hydrochloric acid (pH 4) and water. The solvent is evaporated to a volume of 0.75, and the solution is poured into diethyl ether (4l). The tetra-O-acetyl-penta-N-benzyloxycarbonylcanamycin B precipitate is collected by filtration and dried under vacuum. Yield 244.8 g, 92.6%. WITH). A solution of tetra-0-acetyl-penta-N-benzyloxycarbonylcanamycin B (33.4 g) in tetrahydrofuran (132 ml), water (66 ml) and acetic acid (3.3 ml) is hydrogenated on a catalyst of 5% palladium on activated coal (3.3 g) at a pressure of 3.5 kg / cm for 7 hours. The catalyst is removed by filtration and the filtrate is concentrated to a volume of 25 ml. The residue is treated with ammonium hydroxide (7H, 81.5 MP) and stirred overnight at room temperature. The solution is evaporated to dryness, and the residue is subjected to chromatography on an Amberlite CG-50 ion exchange resin in the form of ammonium ions (2 l), eluting with water and then aqueous ammonia .. 1 fractions containing the desired product are combined and evaporated, with the result that 2,3,6-tri-Y are obtained - acetylcanamycin B (9.37 g, 61.6%), mp 191198 ° C (decomposition, 11 max / KB 1650, 1550 cm, R 0.11 (6 : 3: 1: 2 - methanol: diethyl ether: water; O, 880 aqueous ammonia), R 0.11 (40: 40: 30: 1 meanol: ethyl acetate: water: O, 880 aqueous ammonia). D). To a cooled solution of 2,3,6-tri-N-acetylcanamycin B (93 g) in a mixture of water (465 ml), tetrahydrofuran (558 ml) and triethylamine (154 g) is added in small portions of 40 min (153.1 g). The reaction mixture was stirred at room temperature overnight, and then concentrated to a small volume under reduced pressure. The aqueous concentrate is diluted with isopropanol until precipitation. The NIN of the product is precipitated, the remaining water is removed by azeotropic distillation with isopropanol. Finally, the product is collected by filtering, washed with isopropanol, and dried under vacuum to give 2, 3, b-tri-N-acetyl-1, 3-di-K-formylcanamycin B (89.2 g, so pl. SIO-SIS C () max / KBr 1665, 1545 cm, R 0.49 (6: 3: 1: 2 methanol: diethyl ether: water: 0.880 aqueous ammonia), RjO, 54 (40: 40: 30: 1 methanol: ethyl acetate: water: O, 880 aqueous ammonia). E). The pH of the solution is 2, 3, 3-tri-N-acetyl-. , 322-5 Formylkanamycin B (86.9 gG L of water (2.61 L) is adjusted to 12-12.5. ,, 2gS 4SH | Ie 10 and sodium hydroxide solution | 1. The reaction mixture is kept at room temperature for 4 days The pH of the solution is adjusted to pH 12 with an aqueous solution of sodium hydroxide, if necessary, then the solution is neutralized by adding Amberlite 1R 120 resin (form). The mixture is filtered and the filtrate is subjected to chromatography on Amberlite 200 ion exchange resin (NH form, 5.5 L eluir with water, and then 0.1 N, aqueous ammonium hydroxide solution. After V evaporating the corresponding fractions, 2 ,, 3, b – T are obtained PH-N-acetyl-3-N-formylcanamycin B (55.4 T.P. 266-268 G (pa3JX) VMe, Hc / VHG 1665, 1555 cm Rf 0.49 (40: 40: 30: 1 methanol: ethyl acetate: water: O, 880 aqueous ammonia). Structure confirmed by C-13 NMR spectroscopy. Claim 1. The method for preparing 6 -N-substituent 3-N-formylcanamycin of general formula I where R is an alkanoyl group containing 2-4 atom: carbon, or a benzoyl group, R is a hydroxy group or a group of the formula —NHR, where R is as defined above, characterized in that a compound of the general formula II BUT CJHz NHB, where R and R are indicated. earlier, formulated with 4-nitrophenyl formate in an aqueous organic solvent in the presence of base j, and the resulting compound is selectively hydrolyzed with a dilute solution of sodium or potassium hydroxide at a pH having a value of 12.0 to 12.5.
    [2]
    2. The method according to claim 1, wherein the starting material used is 3,6-di-L-acetylcanane, qing A.
    [3]
    3. The method according to claim 1, in connection with the fact that 2,3, 6-tri-H-acetylcanamycin B is used as the starting compound. Sources of information taken into account in SKcneptMse 1. Buhler k., Pearson D. Organic synthesesiM., Part 1, p. 518.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU873889A3|1981-10-15|Method of preparing 6'-n-substituted-3-n-formylcanamycin
    Kanai et al.1987|Synthesis on 1, 4-Diaminocyclitol Antibiotics. III. Synthesis of 4-Hydroxypurpurosamine B Derivatives
    EP2636411A1|2013-09-11|Epimerization of 4'-c bond and modification of 14-ch3-|-fragment in anthracyclin antibiotics
    US4065615A|1977-12-27|Deoxyaminoglycoside antibiotic derivatives
    AP703A|1998-12-04|Preparation of purines.
    CA1083568A|1980-08-12|Process for the preparation of aminoglycoside antibiotics and novel intermediates therefor
    US4138547A|1979-02-06|Process for preparing 1,2,4-triazole nucleosides
    JP2746997B2|1998-05-06|Method for producing 4-demethoxydaunomycinone
    CS257292B2|1988-04-15|Production method of amikacine
    US4195170A|1980-03-25|3',4'-Episulfido kanamycin B compounds
    Jikihara et al.1973|Studies on Aminosugars. XXXV. Syntheses of 3′, 4′-Dideoxyneamine and 3′-and 4′-O-Methylneamines
    US4879393A|1989-11-07|4-Benzyloxy-3-pyrrolin-2-on-1-yl acetamide production
    US4051315A|1977-09-27|6"-Deoxykanamycin B and 6"-deoxytobramycin
    US3872080A|1975-03-18|Process for the preparation of garamine and intermediates produced thereby
    US4751293A|1988-06-14|Process for preparation of N6 -substituted 3',5'-cyclic adenosine monophosphate and salt thereof
    Ogawa et al.1983|Pseudo-sugars. VIII. Synthesis of DL-1-epivalidamine and related compounds
    US4169939A|1979-10-02|Processes for the production of 3',4'-dideoxykanamycin b
    Kuzuhara et al.1975|Stereoselective synthesis of 5-O-carbamoylpolyoxamic acid (2-amino-5-O-carbamoyl-2-deoxy-l-xylonic acid
    KR820000825B1|1982-05-13|Process for the preparation of 1-n-alkyl-substituted kanamycin derivatives
    US4281107A|1981-07-28|Neamine derivatives and process for preparing the same
    US4357465A|1982-11-02|3',4'-Diedeoxykanamycin B derivatives
    US3873515A|1975-03-25|Process for producing 2,2{40 -anhydro-|cytosine
    US4290972A|1981-09-22|Process for the production of 4-aminobutyric acid or its derivatives
    JPWO2003080561A1|2005-07-21|Manufacturing method of voglibose
    EP1781589B1|2010-04-14|Synthesis of idarubin aglycone
    同族专利:
    公开号 | 公开日
    DK308878A|1979-02-19|
    ES479667A1|1979-08-01|
    ATA590278A|1980-05-15|
    IE47150B1|1983-12-28|
    EG13472A|1981-12-31|
    FI782497A|1979-02-19|
    LU80124A1|1980-04-21|
    NL7808566A|1979-02-20|
    ES472657A1|1979-10-16|
    GR70241B|1982-09-01|
    IE781653L|1979-02-18|
    PT68427A|1978-09-01|
    PL114954B1|1981-03-31|
    JPS5459256A|1979-05-12|
    NO782796L|1979-02-20|
    DD139582A5|1980-01-09|
    US4178437A|1979-12-11|
    SE7808702L|1979-02-19|
    DD148220A5|1981-05-13|
    BE869761A|1979-02-16|
    IT1098281B|1985-09-07|
    DE2835759A1|1979-03-08|
    AT360154B|1980-12-29|
    IT7826812D0|1978-08-17|
    CS201512B2|1980-11-28|
    PL114720B1|1981-02-28|
    PL209082A1|1980-01-02|
    FR2400523A1|1979-03-16|
    AR218324A1|1980-05-30|
    CA1106842A|1981-08-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    NL291070A|1962-04-03|
    JPS5644076B2|1973-07-12|1981-10-16|
    US4029882A|1974-03-19|1977-06-14|Schering Corporation|Selective acylation of the C-1 amino group of aminoglycoside antibiotics|
    US4044123A|1975-05-02|1977-08-23|Schering Corporation|6'-N-alkyl-4,6-di-O--1,3-diaminocyclitols, methods for their use as antibacterial agents and compositions useful therefor|
    NZ184213A|1976-06-16|1980-05-27|Pfizer|2-deoxystreptamine aminoglycosides and antibacterial pharmaceutical compositions|US4493831A|1982-10-25|1985-01-15|Fujisawa Pharmaceutical Co., Ltd.|Aminoglycoside derivatives|
    US7794713B2|2004-04-07|2010-09-14|Lpath, Inc.|Compositions and methods for the treatment and prevention of hyperproliferative diseases|
    US7862812B2|2006-05-31|2011-01-04|Lpath, Inc.|Methods for decreasing immune response and treating immune conditions|
    SI2217610T1|2007-11-21|2017-03-31|Achaogen, Inc.|Antibacterial aminoglycoside analogs|
    WO2010132765A2|2009-05-15|2010-11-18|Achaogen, Inc.|Antibacterial aminoglycoside analogs|
    WO2010132768A1|2009-05-15|2010-11-18|Achaogen, Inc.|Antibacterial derivatives of sisomicin|
    WO2010132757A2|2009-05-15|2010-11-18|Achaogen, Inc.|Antibacterial aminoglycoside analogs|
    WO2010132760A1|2009-05-15|2010-11-18|Achaogen, Inc.|Antibacterial derivatives of tobramycin|
    WO2010132759A1|2009-05-15|2010-11-18|Achaogen, Inc.|Antibacterial derivatives of dibekacin|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB3480877|1977-08-18|
    [返回顶部]